Evidence map›Paper›PMID 38361540›Full record

ArticleGerms2023

Fosfomycin: A potential oral option for treatment of urinary tract infections in Sri Lanka in the context of high antibiotic resistance.

Nishadi Jayathilaka, Tharushi Pathirana, Chathurika Kumari, Varuna Navaratne, Samanmalee Gunasekara, Dilini Nakkawita, Thamarasi Senaratne

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Germs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 65% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 0 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Nishadi JayathilakaBSc (Hons), Medical Laboratory Science, Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Rathmalana, 10390, Sri Lanka.
Tharushi PathiranaBSc (Hons), Medical Laboratory Science, Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Rathmalana, 10390, Sri Lanka.
Chathurika KumariBSc (Hons) Medical Laboratory Science, Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Rathmalana, 10390, Sri Lanka.
Varuna NavaratneMBBS, PG. Dip (Medical Microbiology), MD (Medical Microbiology) BSc, Department of Paraclinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Rathmalana, 10390, Sri Lanka.
Samanmalee GunasekaraMBBS, MD (Medical Microbiology and Bacteriology), Department of Microbiology, National Cancer Institute, Maharagama, 10280, Sri Lanka.
Dilini NakkawitaMBBS, PG. Dip (Medical Microbiology), MD (Medical Microbiology), Dip. RCPath (UK), Department of Paraclinical Sciences, Faculty of Medicine, General Sir John Kotelawala Defence University, Rathmalana, 10390, Sri Lanka.
Thamarasi SenaratnePhD (Medical Virology), MSc (Med Micro), BSc, Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, General Sir John Kotelawala Defence University, Rathmalana, 10390, Sri Lanka.
General Sir John Kotelawala Defence University · LKNational Cancer Institute of Sri Lanka · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Fosfomycin is an effective treatment for urinary tract infections (UTIs). It is not currently used in Sri Lanka to treat UTIs. Hence, this study was conducted to assess the fosfomycin susceptibility for Methods: Results: A total of 101 Conclusions: Fosfomycin is a potential antibiotic option especially for MDR and CR organisms, with 100% in vitro susceptibility. Further studies involving multiple centers, with larger sample size and clinical efficacy studies would be important to assess the potential use of fosfomycin especially for the treatment of UTI-causing MDR and CR organisms.

Indexed as

antibiotic resistantFosfomycinurinary tract infections

Identifiers

PMID38361540
PMCPMC10866161
OpenAlexW4391792515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.